Vinpocetine - instructions for use, dose, side effects, contraindications

Excipients: lactose monohydrate (sugar milk) - 180.0 mg, microcrystalline cellulose (vivapur 102) - 25.0 mg, potato starch - 32.5 mg, magnesium stearate-2.5 mg, talc 5.0 mg.

Description:tablets white or white with a yellowish hue, colors, round, flat-cylindrical, with a facet and a risk.

Pharmacotherapeutic group:cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

The active substance of the drug, having a complex mechanism of therapeutic effect, favorably affects the cerebral circulation, as well as the rheological properties of the blood.

Vinpocetine improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; stimulates the transport of glucose through the blood-brain barrier; translates the process of decay of glucose into an energetically more economical, aerobic pathway.

Selectively blocks Ca2 + -dependent phosphodiesterase, increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of adenosine triphosphate (ATP) and the ratio of ATP / AMP in the brain tissues. Increases the exchange of norepinephrine and serotonin in the brain; stimulates the ascending branch of the noradrenergic system. Has antioxidant effect.

The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels of the predominantly brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, while not changing the blood supply of intact areas. Improves microcirculation in the brain due to a decrease in platelet aggregation, decrease in blood viscosity, increase in the deformability of erythrocytes.Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant effect on the indices of the systemic circulation.

Pharmacokinetics:

-suction: when ingested quickly and completely absorbed in the gastrointestinal tract, mainly in the proximal parts of the small intestine. Bioavailability when taking on an empty stomach - 7%, after meals - about 60%. The maximum concentration in the blood plasma is achieved 1 hour after taking Vinpocetin.

-distribution: easily penetrates through the histohematological barriers (including blood-brain and placental) in the tissue, breast milk. Communication with blood plasma proteins is 66%.

-metabolism: clearance (66.7 l / h) exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism.

-excretion: kidneys and intestines in a ratio of 3: 2. With urine, several percent of Vinpocetin is excreted unchanged, the rest is metabolites.

Half-life is about 5 hours.

Indications:

As a symptomatic tool for various forms of cerebral circulatory insufficiency (including acute and restorative stages of ischemic stroke,restorative stage of hemorrhagic stroke; transient ischemic attack; vascular dementia; posttraumatic and hypertensive encephalopathy);
Vascular diseases of the retina and / or choroid of the eye (due to arteriosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular obturation);
Age-related vascular or toxic (medicamentous) hearing impairment; Ménière's disease, dizziness of a labyrinthine origin; idiopathic noise in the ears.

Contraindications:

hypersensitivity to the components of the drug;
acute stage hemorrhagic stroke, ischemic heart disease (severe course), severe heart rhythm disturbances;
pregnancy, lactation, children under 18 years of age (shortagesaccurate data on the safety of the drug);
lactose intolerance, deficiency lactase, glucose-galactose malabsorption (due to the presence of lactose in the composition preparation).

Pregnancy and lactation:

During pregnancy and lactation, this drug is contraindicated.

Dosing and Administration:

Inside, after eating, 5-10 mg (1-2 tablets) 3 times a day. The initial daily dose is 15 mg. (3 tablets), the maximum daily dose - 30 mg (6 tablets). The duration of the course of treatment is up to 3 months (the course of treatment and dosage are determined by the attending physician). Possible repeated courses 2-3 times a year.

Before cancellation of the drug should gradually reduce the dose.

With kidney and / or liver disease, dose reduction is not required.

Side effects:

From the cardiovascular system: lability (more often decrease) of arterial pressure, tachycardia; extrasystole; depression of the ST segment and prolongation of the Q-T interval on the electrocardiogram.

From the central nervous system: sleep disturbances (insomnia, drowsiness), dizziness, headache, general weakness (may accompany with taking the drug, but more often are symptoms of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

From the skin: redness, skin allergic reactions.

Overdose:Symptoms: increased severity of side effects.

Treatment: gastric lavage, activated charcoal and symptomatic treatment.

Interaction:

Interaction is observed while applying Vinpocetine with glibenclamide, digoxin, acenocoumarol, hydrochlorothiazide, imipramine, with preparations containing pindolol, bupamide.

Perhaps some strengthening of the hypotensive effect with simultaneous application of Vinpocetine with methyldopa (blood pressure control is necessary). Increases the risk of hemorrhagic complications against heparin therapy.

Despite the lack of evidence to support the existence of interaction, caution is recommended, while the use central drugs of antiarrhythmic and anticoagulation action.

Special instructions:

During the period of Vinpocetine treatment, periodic ECG monitoring is necessary in the case of initial interval lengthening Q-T, as well as with the simultaneous use of Vinpocetine with drugs that extend the interval Q-T.

Effect on the ability to drive transp. cf. and fur:

During the period of treatment must be careful when driving, mechanisms and during the occupation of other activities that require concentration and speed of psychomotor reactions.

Form release / dosage:Tablets 5 mg

Packaging:

10 tablets are placed in a contour, cell pack of PVC film and aluminum foil.

2, 3 or 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:In a dry, dark place at a temperature of 2 to 25 ° C. Keep out of the reach of children.

Shelf life:2 years. Do not use after expiry date; indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000182 / 01

Date of registration:16.12.2011

The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia

Manufacturer: & nbsp

MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia

Representation: & nbspMOSHIMFARM PREPARATES them. NA Semashko OJSC MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia

Information update date: & nbsp22.09.2015

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)